Amedisys (Amedisys) Risk Assessment

View and export this data going back to 1994. Start your Free Trial

What is Amedisys Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Amedisys is: Moderate Risk: Sensitive, better choose undervalued stock.

Competitive Comparison of Amedisys's Risk Assessment

For the Medical Care Facilities subindustry, Amedisys's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amedisys's Risk Assessment Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Amedisys's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Amedisys's Risk Assessment falls into.

Amedisys (NAS:AMED) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Amedisys Risk Assessment Related Terms

Thank you for viewing the detailed overview of Amedisys's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Amedisys (Amedisys) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Amedisys Inc (NAS:AMED) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

ADY:Germany ADY:Germany

Address

3854 American Way, Suite A, Baton Rouge, LA, USA, 70816

Website

https://www.amedisys.com

Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, high acuity care segment, and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States, Hospice segment operates many centers designed to provide comfort and support for terminally ill patients, Personal Care Segment provides individuals with assistance in their daily living activities and High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.

Executives

Allyson Guidroz	officer: Chief Accounting Officer	3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Richard M Ashworth	director, officer: President and CEO	200 WILMOT ROAD, DEERFIELD IL 60015
Michael Paul North	officer: Chief Information Officer	3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Adam Y Holton	officer: Chief People Officer	C/O CHS INC., 5500 CENEX DRIVE, INVER GROVE HEIGHTS MN 55077
Denise M. Bohnert	officer: Chief Compliance Officer	3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Nick Muscato	officer: Chief Strategy Officer	3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Richard A Lechleiter	director	PO BOX 32890, LOUISVILLE KY 40232-2890
Bruce D Perkins	director	500 WEST MAIN STREET, LOUISVILLE KY 40202
Christopher Gerard	officer: Chief Operating Officer	3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816
Vickie L Capps	director	2985 SCOTT STREET, VISTA CA 92083
Teresa L. Kline	director	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Jeffrey A Rideout	director	2142 DEER OAK WAY, DANVILLE CA 94506
Julie D Klapstein	director	1239 FRUIT COVE ROAD NORTH, JACKSONVILLE FL 32259
Molly Joel Coye	director	AETNA INC, 151 FARMINGTON AVENUE, HARTFORD CT 06156
David L Kemmerly	officer: See Remarks	3854 AMERICAN WAY, SUITE A, BATON ROUGE LA 70816